The Tumor Glycocode is the next frontier to break through primary & secondary I/O resistant cancers. A highly selective MoA targeting tumor cells through the Tumor Glycocode that also could be used as novel biomarker in diseases such as colorectal cancer.
We are IND-ready
Since 2021 Gnubiotics has been developing a next generation of immunotherapy and now seeks to progress its lead candidate, GNU101, a promising glycopeptide therapeutic to the next step of IND approval and phase 1 trials.
Gnubiotics Sciences SA is partnering with top-tier academic medical centers to move into first clinical trials.
In case you’re interested to learn more about our clinical development plans and indications, please contact us.
Gnubiotics’ breaking new paradigm is the precise selection of O-glycans conjugated to peptides.
As glycopeptides, they unlock the innate immune system to fight the high unmet need in a variety of conditions.
Our glycopeptides have demonstrated biological proof of concept in activating 4 major biological systems. We have mastered the intelligent, rational design and manufacturing of precise complex glycopeptide biologics that target and affect these biological systems. This resulted in a robust pipeline of first-in-class novel glycopeptide therapeutics that are able to activate the adaptive immune system in a range of cancers and conditions with an unprecedented safety profile.
We are impacting 4 areas of high unmet need
through the GENESIS platform:
I/O resistant cancers
Such as colorectal cancer and triple-negative breast cancer
Immuno-Oncology therapy (I/O) resistant cancers developed numerous ways to evade the body’s immune response. The lead glycopeptide formulation GNU101, specifically promotes cytotoxic T-cell activity in the tumor microenvironment and thus overcomes the tumors resistance. GNU101 has been demonstrated to activate antigen presenting cells to instruct cytotoxic T-cells for mounting a stronger response against I/O resistant CRC cancers. Future glycopeptide formulations can be designed to match the glycocode of targets cancer types.
Such as chronic inflammatory bowel disease
In inflammatory bowel disease, various glycopeptide formulations exhibit dual effects by reinforcing gut epithelial barriers and modulating the local immune response. Notably GNU201 has been demonstrated to enhance a reduction in neutrophils migration to the local mucosal inflammation site.
Such as recurring Clostridium difficle infections
The glycopeptides developed by Gnubiotics have been demonstrated to intelligently promote microbiome balance by specifically promoting the growth of beneficial bacteria. Thereby enabling resilience to perturbations like antibiotic treatment and growth opportunistic pathogens like recurrent C. difficile.
Such as obesity
Glyopeptide variants developed by Gnubiotics have been demonstrated to reduce the onset of diet induced obesity and enhance thermogenesis through a number of hypothesized mechanisms of action. Gnubiotics is interested in further investigating this promising MoAs through partnerships and collaborations.
“We are breaking the code, finally uncovering I/O resistant cancers, and activating a targeted & overwhelming T-cell response.”
Dr Yemi Adesokan, CEO
Mechanism of action
GNU101 mediated T-cell response.
Attacking the Tumor Glycocode is a unique first-in-class premise to break through I/O resistance and open a new frontier of novel therapeutics.
Meet the team
Richard comes with more than 3 decades of industry experience. He was CEO of Roche consumer Health and member of the executive board (1999 – 2005), CEO of Nestle Nutrition and member of the executive board (2005 – 2010), CEO of Nobel Biocare AG (2011 – 2016), Chairman of Atkins Nutritional’s (2011 – 2017), among others.
Yemi Adesokan, PhD
Yemi is a world-class award-winning scientist and serial entrepreneur. He has worked with early Startups as well as established late-stage companies where he had responsibilities ranging from IP acquisition and portfolio management to drug launches. Yemi was awarded the 2012 Boston Business Journal 40 under 40 and MIT Tech Review Global Innovators under 35 (TR35 2011). Dr Adesokan earned his PhD from UC Irvine and a Post-Doctoral Fellowship from Harvard Medical School with George Church.
Bernardo Horta e Costa
Prior to co-founding Gnubiotics, Bernardo worked as an investment banker and had an impact as a consultant. Throughout his career, he has gained substantial experience on both buy-and-sell side transactions in a broad range of industries, such as Chemicals, Agribusiness, TMT, Healthcare, Biotech, as well as Food and Beverage across Europe, the US and LatAm, totaling over € 1 billion in transaction and financing value.
Verena Voelter, MD
Verena served as SVP for Novartis Corporation heading the US clinical development and medical affairs organization, prior to which she spent 10 years at Celgene in increasing roles of responsibility in both medical and commercial roles across 3 continents (Europe, Far-East Asia, USA). Today, she is the Founder of 5P Health Care Solutions AG, a boutique consulting firm specialized in negotiation, collaboration, and strategic health care consulting across the entire 5P Value chain: patients, providers, pharma, payers, policy. She is also a thought-after lecturer at renown schools such as Kellogg, ETH. She serves as interim CMO during the the IND-transition.
Ezra has had an extensive and successful career in private equity. He was a partner at ACI Capital from 2001 to 2007, and then at Atlanta-based Roark Capital from 2007 to 2021, where he served in multiple capacities including Chief Investment Officer.
Scientific Advisory Board
Prof Dr James Rothman
Dr. Rothman was a recipient of the 2013 Nobel Prize in Physiology or Medicine and the 2002 Albert Lasker Basic Medical Research. Award.He is the Sterling Professor of Cell Biology at Yale University School of Medicine. Dr. Rothman is the Chair of Arsenal Capital Partners’ Healthcare Advisory Board. Previously he was the Chief Scientist of GE Healthcare and has served in senior advisory roles at Genentech, Merck, GSK, Johnson & Johnson, and Eli Lilly. He was previously a professor at Stanford, Princeton, and Columbia Universities and at Memorial Sloan-Kettering Cancer Center, where he served as Vice-Chairman of the Sloan-Kettering Institute.
Dr John Baldoni
Dr Baldoni held various positions at GSK including SVP, Preclinical Development; VP, Product Development; Director, Product Development; and Ass. Director, Biopharmaceutical Formulation Development, among others. He has worked in the pharmaceutical industry for 42 years. His experience spans new chemical entity design, development & commercialization, and biopharmaceutical development. Dr Baldoni led the innovative drug discovery unit dedicated to exploring and applying in-silico methodology to drug discovery & development at GSK.
Dr Katherine Knobil
Dr Katharine Knobil is CMO at Agilent Technologies. She has more than 20 years of experience in clinical development & medical affairs, leading global strategic leadership roles across functions & geographies. Prior to joining Agilent, Dr Knobil served as CMO and head of R&D at Kaleido Biosciences translating the promise of the microbiome into solutions for patients. Prior to Kaleido, Dr Knobil was CMO at GlaxoSmithKline representing GSK at multiple health authority presentations incl 9 U.S. FDA Advisory Committee Meetings.
Discover AARC 2022 data poster, showcasing groundbreaking insights about Glycopeptides promoting anti-cancer immune response against solid tumors. The poster highlights key findings from the conference, offering a comprehensive snapshot of advancements and innovations...
ASCO captivating data poster, revealing cutting-edge research and pivotal discoveries in the GLAAD molecules domain. 2023 Poster. Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model. Gnubiotics-ASCO-poster-2022Download
Explained: The sugar coating of life Researchers are working to advance the field of glycoscience, illuminating the essential role of carbohydrates for human health and disease. Read the full article:...